{"title":"氟哌噻醇美利曲森治疗成人嗜气症的疗效：一项单中心平行随机对照试验","authors":"Sen-lin Zhu, Ping Li, Hui-wen Xu, Sheng Yao, Lin-lin Huang","doi":"10.1002/jgh3.70199","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study was designed to evaluate the efficacy and safety of short-term flupentixol-melitracen in adult patients with aerophagia through a single-center parallel randomized controlled trial.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Eligible patients were randomly divided into three groups based on the order of subjects. Each group consisted of 30 patients (15F/15M) who received 2 weeks of treatment. Groups 1, 2, and 3 were treated with itopride hydrochloride, flupentixol-melitracen, and the combination of two medicines, respectively. The mean scores of aerophagia symptom relief measured by the visual analogue scale (VAS) after treatment were used as the endpoints.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 90 patients were eligible for the study, of which 76 completed the 2-week treatment period. The scores indicating improvement of aerophagia by VAS showed significant improvement in Group 2 compared with Group 1 (6.92 ± 2.96 vs. 4.58 ± 4.08, <i>p</i> = 0.016) and Group 3 compared with Group 1 (7.34 ± 3.12 vs. 4.58 ± 4.08, <i>p</i> = 0.006). There was no significant difference between Group 2 and Group 3 (6.92 ± 2.96 vs. 7.34 ± 3.12, <i>p</i> = 0.618). The percentage of patients exhibiting scores indicating improvement of aerophagia by VAS ≥ 5 in Group 2 and Group 3 was significantly higher than Group 1 (<i>p</i> = 0.020, <i>p</i> = 0.007). The three groups had similar baseline characteristics and experienced similar non-serious adverse effects during the treatment period.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The findings suggest that short-term treatment with flupentixol-melitracen, with or without a prokinetic benzamide derivative, is likely to improve symptoms of aerophagia in adults without significant adverse effects.</p>\n \n <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: ChiCTR-IPR-15006869</p>\n </section>\n </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 8","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70199","citationCount":"0","resultStr":"{\"title\":\"Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial\",\"authors\":\"Sen-lin Zhu, Ping Li, Hui-wen Xu, Sheng Yao, Lin-lin Huang\",\"doi\":\"10.1002/jgh3.70199\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This study was designed to evaluate the efficacy and safety of short-term flupentixol-melitracen in adult patients with aerophagia through a single-center parallel randomized controlled trial.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Eligible patients were randomly divided into three groups based on the order of subjects. Each group consisted of 30 patients (15F/15M) who received 2 weeks of treatment. Groups 1, 2, and 3 were treated with itopride hydrochloride, flupentixol-melitracen, and the combination of two medicines, respectively. The mean scores of aerophagia symptom relief measured by the visual analogue scale (VAS) after treatment were used as the endpoints.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 90 patients were eligible for the study, of which 76 completed the 2-week treatment period. The scores indicating improvement of aerophagia by VAS showed significant improvement in Group 2 compared with Group 1 (6.92 ± 2.96 vs. 4.58 ± 4.08, <i>p</i> = 0.016) and Group 3 compared with Group 1 (7.34 ± 3.12 vs. 4.58 ± 4.08, <i>p</i> = 0.006). There was no significant difference between Group 2 and Group 3 (6.92 ± 2.96 vs. 7.34 ± 3.12, <i>p</i> = 0.618). The percentage of patients exhibiting scores indicating improvement of aerophagia by VAS ≥ 5 in Group 2 and Group 3 was significantly higher than Group 1 (<i>p</i> = 0.020, <i>p</i> = 0.007). The three groups had similar baseline characteristics and experienced similar non-serious adverse effects during the treatment period.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The findings suggest that short-term treatment with flupentixol-melitracen, with or without a prokinetic benzamide derivative, is likely to improve symptoms of aerophagia in adults without significant adverse effects.</p>\\n \\n <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: ChiCTR-IPR-15006869</p>\\n </section>\\n </div>\",\"PeriodicalId\":45861,\"journal\":{\"name\":\"JGH Open\",\"volume\":\"9 8\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70199\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JGH Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70199\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial
Objective
This study was designed to evaluate the efficacy and safety of short-term flupentixol-melitracen in adult patients with aerophagia through a single-center parallel randomized controlled trial.
Methods
Eligible patients were randomly divided into three groups based on the order of subjects. Each group consisted of 30 patients (15F/15M) who received 2 weeks of treatment. Groups 1, 2, and 3 were treated with itopride hydrochloride, flupentixol-melitracen, and the combination of two medicines, respectively. The mean scores of aerophagia symptom relief measured by the visual analogue scale (VAS) after treatment were used as the endpoints.
Results
A total of 90 patients were eligible for the study, of which 76 completed the 2-week treatment period. The scores indicating improvement of aerophagia by VAS showed significant improvement in Group 2 compared with Group 1 (6.92 ± 2.96 vs. 4.58 ± 4.08, p = 0.016) and Group 3 compared with Group 1 (7.34 ± 3.12 vs. 4.58 ± 4.08, p = 0.006). There was no significant difference between Group 2 and Group 3 (6.92 ± 2.96 vs. 7.34 ± 3.12, p = 0.618). The percentage of patients exhibiting scores indicating improvement of aerophagia by VAS ≥ 5 in Group 2 and Group 3 was significantly higher than Group 1 (p = 0.020, p = 0.007). The three groups had similar baseline characteristics and experienced similar non-serious adverse effects during the treatment period.
Conclusion
The findings suggest that short-term treatment with flupentixol-melitracen, with or without a prokinetic benzamide derivative, is likely to improve symptoms of aerophagia in adults without significant adverse effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
